v3.26.3
Organization, Description of Business and Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Class of Stock [Line Items]          
Number of operating segments | segment     1    
Short-term investments, allowance for expected credit losses $ 0   $ 0   $ 0
Deposits 1,600,000   1,600,000   1,600,000
Total revenue 151,754,000 $ 131,872,000 441,146,000 $ 376,509,000  
Accounts receivable 56,788,000   56,788,000   44,660,000
Other Testing Revenue          
Class of Stock [Line Items]          
Total revenue 2,400,000 1,500,000 11,100,000 3,700,000  
Biopharmaceutical and other revenue          
Class of Stock [Line Items]          
Total revenue 709,000 $ 815,000 1,812,000 $ 8,702,000  
Accounts receivable 2,200,000   2,200,000   3,600,000
Deferred revenue $ 900,000   $ 900,000   $ 1,200,000